SHANGHAI, May 28, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare
services company offering online healthcare information,
professional training and educational services, announced the
launch of the patient management service focusing on the
professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin
Medical Technology Co., Ltd. ("Zhongxin").
Zhongchao has been closely following up on the new study and
research of tumor and rare disease both in China and worldwide. Based on the statistics
provided by World Health Organization's International Agency for
Research on Cancer, there were approximately 19.29 million new
cancer cases and 10 million cancer deaths globally in 2020.
China had approximately 4.57
million new cancer cases in 2020, accounting for approximately
23.7% of the total cancer cases around the world. China's National Health Commission indicated
that there are approximately 20 million patients with rare disease
in China. Medical treatment
markets for both cancer and rare diseases have been expanding along
with the increasing number of patients.
The Company has realized that, in addition to drug development
and more advanced medical treatment options, patients' active
engagements in the treatment is also critical to lead to better
overall treatment outcomes such as higher chemotherapy completion
rate, lower rehospitalization risk and longer survival time. Many
multinational pharmaceutical companies have also realized such
significance by conducting strategic investments in not only drug
developments but also patient management projects.
With our MDMOOC online platform which provides information,
education, and training services for healthcare professionals and
Sunshine Health Forums which provides healthcare knowledge for the
public, the Company could provide technical supports for Zhongxin's patient management services
to assist patients with tumor or rare disease. Zhongxin plans to
build a comprehensive patient management system with integrated
data insights into existing clinical workflows.
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "Zhongxin is built upon
our years of healthcare training service experience and successful
platforms for healthcare professionals and the general public. We
believe that with our patient management services, patients will
have access to holistic and effective treatment systems for
individual well-being, improved patient experience, optimal
allocation of resources and reduced overall costs."
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices
in Shanghai and Beijing, China, Zhongchao Inc. is an
online provider of healthcare information, professional training
and educational services to healthcare professionals under its
"MDMOOC" platform (www.mdmooc.org) and to the public under its
"Sunshine Health Forums" platform (www.ygjkclass.com)
in China. More information about the Company can be found at
its investor relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; economic conditions; the growth
of the professional training and educational services market
in China and the other international markets the Company
plans to serve; reputation and brand; the impact of competition and
pricing; government regulations; fluctuations in general economic
and business conditions in China and the international
markets the Company plans to serve and assumptions underlying or
related to any of the foregoing and other risks contained in
reports filed by the Company with the SEC, the length and
severity of the recent coronavirus outbreak, including its impacts
across our business and operations. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC,
which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:http://www.prnewswire.com/news-releases/zhongchao-inc-launched-new-line-of-business-focusing-on-tumor-and-rare-disease-patient-management-301301482.html
SOURCE Zhongchao Inc.